Nurtec ODT vs Ubrelvy
Both are CGRP inhibitors. Here is how Nurtec ODT and Ubrelvy compare on class, mechanism, dosing, approval and supply.
At a glance
Key differences
- Same class. Both Nurtec ODT and Ubrelvy are CGRP inhibitors, so they work through the same broad mechanism. Differences between them tend to be about dosing, route, how selective they are, and side effects rather than what they target.
- Time on the market. Nurtec ODT was first approved by the FDA in 2020, Ubrelvy in 2019.
- Who markets them. Nurtec ODT is marketed by Pfizer; Ubrelvy by AbbVie.
- Same drug, more than one brand. Rimegepant is sold as Nurtec ODT / Vydura — the same active ingredient marketed under different brand names, typically for different approved uses or doses.
What each one treats
NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: acute treatment of migraine with or without aura in adults ( 1.1 ) preventive treatment of episodic migraine in adults ( 1.2 ) 1.1 Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults . 1.2 Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.
An oral acute medication taken at the onset of migraine headaches to relieve pain.
How each one works
12.1 Mechanism of Action Rimegepant is a calcitonin gene-related peptide receptor antagonist.
An oral acute medication taken at the onset of migraine headaches to relieve pain.
Related comparisons
Read more
Which medicine is right for a given person depends on their diagnosis, other conditions, other medicines, kidney and liver function, pregnancy, and cost or reimbursement — none of which this page knows. Two drugs in the same class are not automatically interchangeable. Never start, stop or switch a prescription medicine on the basis of a web page; that decision belongs to you and your clinician or pharmacist.
How this page is built
The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.
- FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
- Drugs@FDA ↗ First FDA approval date and the company holding the application
- FDA Drug Shortage Database ↗ Current US supply / shortage status
Plain-English summaries and drug-class explainers are written and reviewed by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 7 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.